Investigational Drug Information for Linerixibat
✉ Email this page to a colleague
What is the development status for investigational drug Linerixibat?
Linerixibat is an investigational drug.
There have been 7 clinical trials for Linerixibat.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 27th 2021.
The most common disease conditions in clinical trials are Pruritus, Cholestasis, and Liver Cirrhosis, Biliary. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].
There are two US patents protecting this investigational drug and sixty-eight international patents.
Summary for Linerixibat
| US Patents | 2 |
| International Patents | 68 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-08-27) |
| Vendors | 35 |
Recent Clinical Trials for Linerixibat
| Title | Sponsor | Phase |
|---|---|---|
| Food Effect Study of Linerixibat Tablets in Healthy Adult Participants | GlaxoSmithKline | Phase 1 |
| Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls | GlaxoSmithKline | Phase 1 |
| Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants | GlaxoSmithKline | Phase 1 |
Clinical Trial Summary for Linerixibat
Top disease conditions for Linerixibat
Top clinical trial sponsors for Linerixibat
US Patents for Linerixibat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Linerixibat | ⤷ Sign Up | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (Foster City, CA) | ⤷ Sign Up |
| Linerixibat | ⤷ Sign Up | Chemical compounds | GlaxoSmithKline LLC (Wilmington, New Castle, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Linerixibat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Linerixibat | Australia | AU2020221239 | 2039-02-12 | ⤷ Sign Up |
| Linerixibat | Australia | AU2020221834 | 2039-02-12 | ⤷ Sign Up |
| Linerixibat | Australia | AU2020223022 | 2039-02-12 | ⤷ Sign Up |
| Linerixibat | Brazil | BR112021015799 | 2039-02-12 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
